Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Mappa di calore
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
HQL
#6514
abrdn Life Sciences Investors
17.7
3
USD
+1.43%
Settore:
Finanziario
Base:
USD
Valuta di Profitto:
USD
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
+1.43%
Variazione Mensile
+8.04%
Variazione di 6 mesi
+9.11%
Variazione Annuale
+50.00%
Chiusura Precedente
17.4
8
Apertura
17.7
5
Bid
Ask
Minimo
17.7
3
High
17.7
7
Volume
31
Mercati
Mercato Azionario Statunitense
Finanziario
HQL
Apri il grafico completo
Principali partecipazioni
Market Value
Shares
Weight %
uniQure NV
38.450 M
658.737 K
7.492%
VRTX
Vertex Pharmaceuticals Inc
17.165 M
43.829 K
3.345%
AMGN
Amgen Inc
15.414 M
54.622 K
3.004%
ALNY
Alnylam Pharmaceuticals Inc
15.342 M
33.645 K
2.989%
INSM
Insmed Inc
14.546 M
101.010 K
2.834%
ARGX
Argenx SE
13.961 M
18.929 K
2.720%
REGN
Regeneron Pharmaceuticals Inc
13.455 M
23.930 K
2.622%
NEUROVANCE MILESTONE INTEREST
11.172 M
34.055 K
2.177%
CYTK
Cytokinetics Inc
10.863 M
197.644 K
2.117%
RARE
Ultragenyx Pharmaceutical Inc
10.501 M
349.116 K
2.046%
SION
Sionna Therapeutics Inc
8.508 M
289.277 K
1.658%
XENE
Xenon Pharmaceuticals Inc
8.504 M
211.804 K
1.657%
Akero Therapeutics Inc
8.459 M
178.163 K
1.648%
State Street Global Advisors
8.417 M
8.417 M
1.640%
PCVX
Vaxcyte Inc
8.292 M
230.213 K
1.616%
SMMT
Summit Therapeutics Inc
8.137 M
393.856 K
1.586%
BNTX
BioNTech SE
7.726 M
78.339 K
1.505%
ARWR
Arrowhead Pharmaceuticals Inc
7.347 M
213.011 K
1.432%
TVTX
Travere Therapeutics Inc
7.212 M
301.778 K
1.405%
DYN
Dyne Therapeutics Inc
7.043 M
556.733 K
1.372%
Notizie
10 Best CEFs This Month: Average Yield Of 10% (March 2026)
The $500,000 Portfolio To Potentially Pay All Your Bills
10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)
Abrdn Life Sciences Investors Fund Q4 2025 Commentary (HQL)
HQL CEF: Dividend Can Be Sustained Through 2026 (NYSE:HQL)
Abrdn Life Sciences Investors Q3 2025 Commentary (NYSE:HQL)
HQH: Severely Underperforms Peers (NYSE:HQH)
HQL: We Should Be Accumulating During The Weakness (NYSE:HQL)
CEF Insights: The Future Of Healthcare Investing
HQL: Positive Outlook Due To Increased Healthcare Spending (NYSE:HQL)
The India Fund Q1 2025 Commentary
abrdn Ultra Short Municipal Income Fund Q1 2025 Commentary